B-Cell Lymphomas

Common Name(s)

B-Cell Lymphomas

Lymphoma is the most common blood cancer. Lymphocytes are a type of white blood cell that are part of our body’s immune system and help our body fight infections. Lymphoma occurs when these lymphocytes grow and multiply uncontrollably. The body has two main types of lymphocytes, B-lymphocytes (B-cells) and T-lymphocytes (T-cells). B-cell lymphoma occurs when the B-cells in particular grow into lymphomas. The cancerous lymphocyte cells can then travel to various parts of the body including the lymph nodes, blood, spleen, bone marrow and other organs. There are many different types of B-cell lymphomas and the most common type is called diffuse large b-cell lymphoma (DLBCL) which is aggressive (fast-growing) and requires immediate treatment. There are other forms that are slow-growing and respond well to treatment and can go into remission for many years. Genetic factors as well as environmental factors, weak immune system (immunodeficiency due to an organ transplant or HIV/AIDS), drug and chemical exposures, viruses and other unknown factors are thought to play a role in the development of lymphoma.

Symptoms are variable but can include: swollen lymph glands, fevers, night sweats, fatigue, unexplained weight loss, pain or abdominal bloating, chest pain, cough, difficulty breathing. Diagnosis may include physical exam of the lymph nodes, spleen and liver, blood tests, x-rays, scans, and finally a biopsy from lymph tissue. The treatment and prognosis or outlook depends upon the specific type of B-cell lymphoma and other factors present but often includes radiation, chemotherapy and medications. Speak with your physician for the most current treatment options. Support groups are also a great resource for support and information and can help connect you to other individuals with B-cell lymphoma.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "B-Cell Lymphomas" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "B-Cell Lymphomas" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "B-Cell Lymphomas" returned 579 free, full-text research articles on human participants. First 3 results:

Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.
 

Author(s): Ana-Iris Schiefer, Christoph Kornauth, Ingrid Simonitsch-Klupp, Cathrin Skrabs, Eva Katharina Masel, Berthold Streubel, Katrina Vanura, Karin Walter, Brigitta Migschitz, Dagmar Stoiber, Veronika Sexl, Markus Raderer, Andreas Chott, Maria Gomes da Silva, Jose Cabecadas, Leonhard Müllauer, Ulrich Jäger, Edit Porpaczy

Journal: Medicine (Baltimore). 2015 Dec;94(52):e2388.

 

MYC and BCL2 translocations as well as TP53 deletion/mutation are known risk factors in diffuse large B-cell lymphoma (DLBCL) but their interplay is not well understood.In this retrospective cohort study, we evaluated the combined prognostic impact of TP53 deletion and mutation status, ...

Last Updated: 31 Dec 2015

Go To URL
Inconclusive flow cytometric surface light chain results; can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas?
 

Author(s): Andreja Brozic, Ziva Pohar Marinsek, Srdjan Novakovic, Veronika Kloboves Prevodnik

Journal:

 

Flow cytometric immunophenotyping (FCI), is widely used in cytology for distinguishing between B-cell lymphoma (BCL) and reactive lymphocytic proliferations (RLP), mainly by identifying monotypic B-cell populations. Since this cannot always be determined by ratios of surface immunoglobulin ...

Last Updated: 20 Oct 2015

Go To URL
ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans.
 

Author(s): Karen S Hathcock, Hesed M Padilla-Nash, Jordi Camps, Dong-Mi Shin, Daniel Triner, Arthur L Shaffer, Robert W Maul, Seth M Steinberg, Patricia J Gearhart, Louis M Staudt, Herbert C Morse, Thomas Ried, Richard J Hodes

Journal: Blood. 2015 Nov;126(20):2291-301.

 

The serine-threonine kinase ataxia-telangiectasia mutated (ATM) plays a central role in maintaining genomic integrity. In mice, ATM deficiency is exclusively associated with T-cell lymphoma development, whereas B-cell tumors predominate in human ataxia-telangiectasia patients. We ...

Last Updated: 13 Nov 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "B-Cell Lymphomas" returned 39 free, full-text review articles on human participants. First 3 results:

Cutaneous primary B-cell lymphomas: from diagnosis to treatment.
 

Author(s): Margarida Lima

Journal: An Bras Dermatol. ;90(5):687-706.

 

Primary cutaneous B-cell lymphomas are a heterogeneous group of mature B-cells neoplasms with tropism for the skin, whose biology and clinical course differ significantly from the equivalent nodal lymphomas. The most indolent forms comprise the primary cutaneous marginal zone and ...

Last Updated: 12 Nov 2015

Go To URL
Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.
 

Author(s): M A Lunning, M R Green

Journal:

 

Subtypes of non-Hodgkin's lymphomas align with different stages of B-cell development. Germinal center B-cell (GCB)-like diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Burkitt's lymphoma (BL) each share molecular similarities with normal GCB cells. Recent next-generation ...

Last Updated: 17 Oct 2015

Go To URL
Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.
 

Author(s): Jonathan W Friedberg

Journal: Chin Clin Oncol. 2015 Mar;4(1):9.

 

Although diffuse large B-cell lymphoma (DLBCL) is curable with standard chemoimmunotherapy, over 30% of patients with advanced stage disease experience refractory disease or progression. Recent studies suggest that rearrangement of the myc oncogene occurs in approximately 10% of patients ...

Last Updated: 6 Apr 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
 

Status: Recruiting

Condition Summary: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia

 

Last Updated: 14 Jun 2016

Go to URL
AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
 

Status: Not yet recruiting

Condition Summary: Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma; Module 1: Non-GCB Diffuse Large B-Cell Lymphoma

 

Last Updated: 19 May 2016

Go to URL
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
 

Status: Recruiting

Condition Summary: Diffuse Large B Cell Lymphoma Relapsed; Diffuse Large B Cell Lymphoma Refractory

 

Last Updated: 1 Jun 2016

Go to URL